<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01632397</url>
  </required_header>
  <id_info>
    <org_study_id>1R34MH095584-01</org_study_id>
    <nct_id>NCT01632397</nct_id>
  </id_info>
  <brief_title>Pre-exposure Prophylaxis Adherence Intervention for MSM</brief_title>
  <acronym>PrEPare</acronym>
  <official_title>Optimizing Antiretroviral-Based Prevention by Enhancing PrEP Adherence in MSM</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fenway Community Health</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Fenway Community Health</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Following formative work, the proposed study is an open-label, pilot, randomized, two arm
      trial where subjects will receive pre-exposure prophylaxis (PrEP) for 6 months and either a
      cognitive-behavioral based adherence intervention or health education with supportive
      counseling.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>August 2011</start_date>
  <completion_date type="Actual">February 2014</completion_date>
  <primary_completion_date type="Actual">February 2014</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Adherence to PrEP over time</measure>
    <time_frame>At each of the 7 study visits post PrEP perscrition spread over the duration of the study (up to six months)</time_frame>
    <description>This is primarily a feasiblity pilot RCT. However, the primary eventual endpoint is PrEP adherence measured daily via electronic medication adherence monitoring (Wisepillâ„¢).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Sexual Risk Compensation</measure>
    <time_frame>At each of the 9 study visits spread over up to six months.</time_frame>
    <description>This is primarily a feasiblity RCT. Sexual risk compensation is defined as a potential change in sexual risk taking behaviors (unprotected anal sex). This is measured daily with text message assessments for sexual risk as well as at each study visit with self-report measure(s).</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">103</enrollment>
  <condition>Medication Adherence</condition>
  <arm_group>
    <arm_group_label>CBT-based counseling</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Cognitive behavioral based intervention to promote PrEP adherence.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Health education and supportive counseling</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Time matched supportive counseling</description>
  </arm_group>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>CBT-based counseling</intervention_name>
    <description>Cognitive Behavior Therapy for PrEP adherence</description>
    <arm_group_label>CBT-based counseling</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Health education and supportive counseling</intervention_name>
    <description>Time matched general supportive therapy of the type commonly available from community therapists.</description>
    <arm_group_label>Health education and supportive counseling</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  male sex at birth

          -  being 18 years old or older

          -  testing HIV-negative at screening

          -  evidence of high risk for HIV acquisition defined by having unprotected anal sex
             (insertive or receptive) with an HIV-positive male partner OR at least a total of
             three episodes of unprotected anal sex with at least two partners in the last three
             months

          -  medically cleared to take the study drug (ambulatory performance &gt;=60 on Karnofsky
             scale, adequate renal function, negative glucose and protein in urine, adequate
             hepatic function, adequate hematologic function)

          -  able to understand and speak English (for consenting and counseling).

        Exclusion Criteria:

          -  participants who are not able to consent due to psychiatric or cognitive concerns

          -  those who have already been prescribed PrEP

          -  having a history of or current medical conditions that would preclude taking the study
             drug (e.g., previously diagnosed active and serious infections, acute or chronic
             hepatitis B, history of pathological bone fractures not related to trauma)

          -  receiving ongoing therapy with ART, other agents with significant nephrotoxic
             potential, other agents that may inhibit or compete for elimination via active renal
             tubular secretion, or other investigational agents

          -  receiving or possibly receiving antiretroviral drugs for an anti-HIV vaccine in a
             clinical trial

          -  active alcohol or drug use that would interfere with study participation

          -  having other conditions (based on opinion of investigator or designee) that would
             preclude informed consent, make the study unsafe, complicate interpretation of study
             outcome data, or otherwise interfere with study procedures
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kenneth Mayer, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Fenway Health</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>The Fenway Institute</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02215</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.ncbi.nlm.nih.gov/pubmed/21091279</url>
  </link>
  <verification_date>February 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 8, 2012</study_first_submitted>
  <study_first_submitted_qc>June 28, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 2, 2012</study_first_posted>
  <last_update_submitted>February 8, 2016</last_update_submitted>
  <last_update_submitted_qc>February 8, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 9, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Fenway Community Health</investigator_affiliation>
    <investigator_full_name>Kenneth H. Mayer, MD</investigator_full_name>
    <investigator_title>Medical Research Director, Co-Chair of The Fenway Institute</investigator_title>
  </responsible_party>
  <keyword>PrEP</keyword>
  <keyword>HIV</keyword>
  <keyword>Adherence</keyword>
  <keyword>MSM</keyword>
  <keyword>Men having sex with men</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

